Free Publications

Search for cll returned 221 results

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.

#ASH16 (Blog 3): Teaming Up to Beat AML

This is the third in a series of blogs covering the 58th ASH Annual Meeting and Exposition (#ASH16). LLS’s groundbreaking precision medicine clinical trial in acute myeloid leukemia (AML), “has the potential to change the paradigm of AML and other hematologic malignancies,” said Kenneth Anderson,  M.D., Dana-Farber Cancer Institute, during a press briefing today at the 58th ASH Annual Meeting and Exhibition in San Diego. Dr. Anderson, president-elect of ASH (t ...

Read more

Game-Changing Cancer Progress Presented at AACR

More than 20,000 cancer scientists from around the globe came to Chicago this week to share and learn about the latest advances in research and treatments at the annual meeting of the American Association of Cancer Research (AACR). AACR is one of the world’s oldest and largest nonprofits dedicated to cancer research and education. Blood cancers were among the thousands of scientific presentations and educational sessions. And while much of the excitement focused on lung cancer and ...

Read more

Quest for CURES (Closed)

Identify and develop safer, more effective treatment paradigms for patients with hematological malignancies.

LLS has formed a partnership with Celgene to create the first of such RFPs that will build the foundation of this new LLS initiative. This initiative will identify and fund priority research areas, with support from biotech and pharmaceutical partners in order to address significant unmet medical needs. The near-term goal of this program is to advance the scientific and medica ...

  • Photo
Read more

Our History

Hope Rises from Loss The Leukemia & Lymphoma Society (LLS) was born out of a family's grief following the death of their teenage son. RobbieRobert Roesler de Villiers, son of a well-to-do New York family, was only 16 when he quickly succumbed to leukemia in 1944. Five years later, frustrated by the lack of effective treatments for what was then considered a hopeless disease, parents Rudolph and Antoinette de Villiers started a fundraising and education organization in their son's ...

  • Photo
Read more

A History of Research Innovations

Witness the impact LLS has had over decades in the fight against cancer. 1946 | William Dameshek, MD In 1946, studies by William Dameshek, MD, who later served as an advisor to the Leukemia Society of America, led to the first anti-cancer chemotherapy. 1949 | The Leukemia Society founded In 1944, the de Villiers family loses their teenage son, Robert Roesler, to leukemia. In 1949, led by the de Villiers' family, who lo ...

  • Photo
Read more

Pages

Glossary Results

Relapsed CLL

CLL that responded to treatment but then returns.

Refractory CLL

CLL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

CD38

An antigen on CLL cells and other cells. The expression of CD38 may be a marker to assist in predicting CLL progression.

Richter transformation

In a small number of patients, there is a progression in their disease. In these patients, CLL takes on the characteristics of an aggressive lymphoma. This change is not a second cancer, but a transformation of the CLL cells.

Small lymphocytic lymphoma (SLL)

A disease with symptoms and treatment that are much like CLL. SLL starts in a lymphocyte in a lymph node. CLL starts in a lymphocyte in the marrow.

Immunoglobulin Heavy Chain Variable Region (IgHv) Gene Status

A marker that can distinguish between CLL subtypes (unmutated IgHv and mutated IgHv). People with CLL with unmutated IgHv gene status may have a more progressive form of the disease.

Zap-70

An abbreviation for the cell protein “zeta-associated protein 70.” A high level of ZAP-70 expression on the cells of patients with B-cell CLL is one of several factors that may predict more progressive disease. Outside of a research laboratory this test is generally not very reliable and should not be used.